ClinicalTrials.gg
RecruitingNCT07404514ULNEERUpdated Aug 24, 2026

Longitudinal Ulnar Deficit (ULNEER)

An observational study in Ulnar Longitudinal Deficiency and Ulnar Hand Deformity, sponsored by Hopitaux de Saint-Maurice. Recruiting at 1 site in France. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by Hopitaux de Saint-Maurice · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
28
Ages
3 Years to 18 Years
Sex
All
01

Study summary

The management of patients with longitudinal ulnar deficiency is a clinical challenge due to the rarity of this condition and the wide variety of its manifestations. In particular, there is no consensus in the literature on the indications for surgery.

The aim of this research is to improve understanding and management of this malformation by analyzing existing data from patient medical follow-up.

No new clinical evaluations or occupational therapy assessments will be performed specifically for this study.

The analysis will be based on previous medical and paramedical data (consultation reports, imaging, occupational therapy assessments, etc.) in order to better describe the functional evolution of patients and identify the decision-making criteria that guide surgical management.

Parents will also receive standardized questionnaires (PROMIS and ABILHAND-Kids-CP) to gather their perceptions of their child's quality of life and independence.

The results will be used to propose recommendations for a more consistent and multidisciplinary assessment of longitudinal ulnar deficit in the future.

02

Conditions studied

  • Ulnar Longitudinal Deficiency
  • Ulnar Hand Deformity

Keywords

  • Ulnar longitudinal deficit
  • Upper limb deficiency
  • Pediatric upper limb
  • Occupational therapy
  • ABILHAND-Kids
  • PROMIS
03

In context

Lead sponsor

Hopitaux de Saint-Maurice is the lead sponsor of 16 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of children and adolescents aged 3 to 18 years diagnosed with ulnar longitudinal deficiency, either unilateral or bilateral.

Participants are followed at a tertiary referral center for upper limb malformations and have available medical records allowing retrospective data extraction. Parent-reported outcome measures are collected prospectively as part of the study without modifying standard clinical care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with unilateral or bilateral ulnar hand deformity, whether operated on or not
  • Follow-up at CEREFAM and/or Trousseau Hospital
  • Complete medical records containing previous assessments

Exclusion criteria

Exclusion Criteria:

  • Non-French-speaking patient
  • No preoperative or postoperative assessment
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
28 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ulnar Longitudinal Deficiency Observational Cohort

    This arm represents a non-interventional observational cohort of children and adolescents with ulnar longitudinal deficiency. No intervention is assigned as part of the study. Clinical, radiological, and rehabilitation data are collected retrospectively from existing medical records and prospectively through parent-reported outcome questionnaires (PROMIS and ABILHAND-Kids-CP), without any modification of standard clinical care.

06

What researchers measure

Primary outcomes

  1. Upper limb function and health-related quality of life (PROMIS Upper Extremity and ABILHAND-Kids)

    Upper limb function and health-related quality of life will be assessed using validated parent-reported outcome measures: * The Pediatric Outcomes Measurement Information System (PROMIS) Upper Extremity Pediatric questionnaire. PROMIS scores are standardized T-scores with a mean of 50 and a standard deviation of 10 in the reference population. Scores typically range from approximately 0 to 100, with higher scores indicating better upper limb function. * The ABILHAND-Kids questionnaire (Assessment of Manual Ability for Children). ABILHAND-Kids scores are converted into a scaled measure ranging from 0 to 100, with higher scores indicating better manual ability.

    Time frame: From baseline to study completion (up to 10 months)

Secondary outcomes

  1. Upper limb functional ability score

    Upper limb functional ability will be assessed using the ABILHAND-Kids questionnaire (Assessment of Manual Ability for Children). Scores are converted into a scaled measure ranging from 0 to 100, with higher scores indicating better manual ability.

    Time frame: From baseline to study completion (up to 10 months)

  2. Pediatric upper limb function

    Upper limb function will be assessed using the Pediatric Outcomes Measurement Information System (PROMIS) Upper Extremity Pediatric questionnaire. PROMIS scores are standardized T-scores with a mean of 50 and a standard deviation of 10 in the reference population. Scores typically range from approximately 0 to 100, with higher scores indicating better upper limb function.

    Time frame: From baseline to study completion (up to 10 months)

  3. Pediatric health-related quality of life

    Health-related quality of life will be assessed using the Pediatric Outcomes Measurement Information System (PROMIS) Pediatric Global Health questionnaire. PROMIS scores are standardized T-scores with a mean of 50 and a standard deviation of 10 in the reference population. Scores typically range from approximately 0 to 100, with higher scores indicating better health-related quality of life.

    Time frame: From baseline to study completion (up to 10 months)

07

Study locations

1 of 1 sites recruiting
  • Hôpitaux Paris Est Val-de-Marne - Centre de Référence des Malformations des Membres
    Saint-Maurice, 94410, France
    Recruiting
    • Adrien AL Leluc, MD · ContactAdrien.leluc@gmail.com · +33 6 06 99 96 74
    • Adrien AL Leluc, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared due to the small sample size, the pediatric population involved, and the need to ensure participant confidentiality in accordance with applicable data protection regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2026 to primary completion in May 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 11, 2026
StartActual
Feb 12, 2026
Primary completionActual
May 30, 2026
CompletionEst.
Sep 2026
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07404514
Lead sponsor
Hopitaux de Saint-Maurice
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 12, 2026
Primary completion
May 30, 2026
Completion
Sep 2026 (estimated)
Last update
Aug 24, 2026

Study contacts

Auriane AS SLAMA
Contact
auriane.slama@ght94n.fr
0143967556

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion